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ABSTRACT

Chronic pain is a complicated, completely unknown condition that has been studied
based on its severe impact on the population. According to the American Academy of Pain
Medicine, 1.5 billion people suffer from tension-type headaches, one of the most common
symptomatic chronic conditions. Christopher L. Cioffi, 2019; mentioned approximately in
US 116 million adults are explicitly afflicted by chronic pain. Chronic pain is described as
dysfunction in nerves that have been continuous during a long period (Mills, 2019).
Treatments for chronic pain are different types of common analgesics that relieve the
pain for short periods such as aspirin, ibuprofen, paracetamol, etc. (Hunging, 2017) Accord to
the level of it, such as opioids, anticonvulsants drugs, antidepressants, and anti-inflammatory
drugs are some of the treatments used for severe pain. One of the most common therapies is
opioids, as relievers of pain available legally by prescription. Opioids are considered one of
the most effective drugs for the treatment of several levels of pain (Wood, 2019). In most of
the world, opioids have been the solution to controlling severe or constant pain, such as
chronic pain.
The several side effects that opioids produce create several concerns related to patient
safety and abuse addiction. (Rosenblum, Marsch, Joseph, & Portenoy, 2008) Secondary side
effects that do not let opioids be a correct option for chronic pain treatment are diverse; for
example, the high rate of addiction or possible drug abuse (Edlund, 2007). "Injury to the
somatosensory system (neuropathic pain), degenerative processes and chronic inflammation
(i.e., osteoarthritis and rheumatoid arthritis), disease (i.e., cancer pain)" (Cioffi, 2019) are
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some of the suggested risks or suffer chronic pain and the analgesic resistance that patients
development through their fight with the problem makes harder to avoid the use of opioids.
Therefore, several research types are interested in finding new therapies that avoid the
use of opioids—looking for better options to find relief for those patients who continuously
are suffering from pain. The virtual screening method developed achieved a high hit rate of
75%. By analyzing more and more new compounds and looking for possible chronic pain
treatment targets, the discovery of a group of new compounds with good inhibitory properties
and selectivity it seems to be possible. Hit1 is considered to be the first and main candidate
for further optimization of potential customers and detailed, more specific analysis of the
ligand. We observed that some of the factors that make Hit1 the main ligand, such as the
stable hydrogen bond that interacts with glycine transporter 2, showed a development similar
to ALX1393 activity. Through several MD simulations. The results provided a structural
basis for the Hit1 selectivity observed experimentally in GlyT2. The result displayed by Hit2
is closest to Hit1. The inhibition of glycine transporters, especially glycine transporter 2
(GlyT2), has been shown promise for new treatments for chronic pain based on their role in
the neurotransmission of pain signals. They are improving the knowledge in better ways to
find cures for chronic pain with fewer consequences in the process.
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CHAPTER I- INTRODUCTION

Chronic pain has been mysterious and complicated to understand the condition, and
through the years, the rate of people suffering from this condition have been increasing (Seth,
2016). Nerve damage due to injury or disease, causing deep and intense pain, with a time
prolongation higher than 12 weeks is considered chronic pain (Weatherspoon, 2017). There
are various treatments for chronic pain, some more efficient than others, such as opioids,
antidepressants, or anti-inflammatory drugs. All these previous therapies have side effects
such as short time of pain relief, high addiction levels, etc. (Edlund, 2007). Scientists are
interested in developing new therapies that avoid the use of opioids and other analgesics,
preventing their dangerous side effects.
The opioids in the central nervous system have a fascinating interaction with its close
interaction with the limbic areas such as the amygdala or some glands like the pituitary and
adrenal glands(Proehlich, 2017). Showing the problematic division between scientists on its
administration as a treatment for some chronic diseases, that every year more frequently
overdoses cases related to opiates intake are present in society(Kopec et al., 2009).
Then, glycine is a major inhibitory neurotransmitter in the vertebrate central nervous
system. It is known to act as an inhibitory transmitter via its interaction with
strychnine-sensitive glycine receptors (Hashimoto, 2010). Two glycine transporters control
its extracellular levels, glycine transporter 1 and glycine transporter 2 (GlyT1 and GlyT2,
respectively).
Glycine is involved in the synapse based on the termination by its rapid reuptake into the
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nerve terminal and adjacent glial cells. Glycine transporters have been analyzed for several
reasons, having essential importance in the pharmacology field because of its emerging
relevance in relationship with some neurological diseases such as chronic pain.
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SYNAPTIC INTERACTION OF GLYCINE

Figur e 1. Glycine neur otr ansmission at excitator y and inhibitor y synapses. After glycine
release into the synapse, it binds to glycine receptors (GlyRs) located in the postsynaptic
terminals. The glycine levels at the glycinergic synapses returned to normal levels by specific
glycinergic transporters (GlyT1 and GlyT2) in the presynaptic terminal for GlyT2 and GlyT1
in glial cells and astrocytes.
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The inhibition of glycine transporters has been established several neuronal damages
shown by several animal experiments, whereby the inhibition of GlyT, mice die due to
respiratory arrest (Schwarcz, 2016). The transmission of pain signals in the brain presents a
co-relation with GlyT2; the inhibition of GlyT2 causes an increase in glycine levels in the
synaptic cleft that results in prolonged activation of glycine receptors onto pain fibers and
decreases the pain signal in the central nervous system (CNS). Chronic pain has been studied
for its development through years around the population of different ages affecting up to 30%
of those aged 18-39 yr (Mills, 2019). As a persistent pain caused by damage in a nerve on the
peripheral or central nervous system and without efficient treatments (Vandenberg et al.,
2014), GlyT2 inhibition is a promising effective treatment against it.
1.1 Solute Car r ier 6 Family (SLC6)
GlyT1 and GlyT2 are secondary active transporters and belongs to the Solute Carrier 6
Family (SLC6). The SLC6 family characterized themselves as secondary active
co-transporters that depend on the Na+/Cl- concentration gradient. Akula Bala et al., 2013
analyzed the SLC6 family and mentioned four different subgroups. The neurotransmitter
transporters are formed by the glycine transporters, the amino acid transporters, the osmolyte
transporters, and creatine transporters, and the orphan transporters in which no substrates
have been identified (Thimgan, 2006). This SLC6 family has significant relevance in the
clinical aspect by its localization around the body, such as, "nervous system, kidney, intestine,
pancreas, adrenal gland, and testis" (Akula et al., 2013). As can be analyzed, the SLC6 family
is fundamental in understanding how glycine's development in the central nervous system
works at the molecular level. The analysis of which family comes from glycine transporters
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helps research and analyze how possible it can do. Having the antecedent of how the structure
of glycine transporters is, it proposes a better idea of how the interaction of those transporters
works around several amino acids, useful in better knowledge of them. In order to find a
connection between glycine transport and treatment for neurological diseases and understand
the physiology of glycine transporters being very similar, everything makes more challenging
the development of new therapies.
1.2 Glycine Tr anspor ter s differ ence and char acter istics
The glycine transporters share several similitudes that complicate the development of
specific treatments for each one in pharmacology. The creation of specific inhibitors for each
glycine transporter without damaging the molecular development of the opposite one is the
next step on emerging treatments with high specificity and better results against diseases.
GlyT1 needs two sodium ions; on the other hand, GlyT2 requires three sodium ions to
transport one molecule of glycine. Also, glycine plays an essential role in excitatory
neurotransmission

with

its

interaction

in

the

glycine

sites

located

on

the

N-methyl-D-aspartate (NMDA) receptors, the three ionic glutamate receptors (VanDongen,
2009). GlyT-1 and GlyT-2 share 12 putative transmembrane spanning domains and
approximately 50% amino acid sequence identity. Those transporters differ in several aspects.
For example, they are different thermodynamically coupled to the sodium electrochemical
gradient, GlyT1 needs two sodium ions, and GlyT2 requires three sodium ions for the
transport of their residues.
Although their structures have shared several similitudes (Zafra, 2008), the plasma
membrane distribution on glycine transporters differs, finding a specific interaction of GlyT2
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with glycinergic neurons in the spinal cord, the brainstem, and the cerebellum, where is
possible to locate the protein enriched in the presynaptic terminals (Zafra, 2008). Contrarily,
in glial cells (the most abundant cell types in the CNS and responsible for homeostasis
maintenance), GlyT1 is mainly concentrated in glutamatergic terminals at lower levels (Zafra,
2008). The analysis of GlyT2 relevant functions during the neurotransmission is an iconic
beginning in the search about its appropriate utilization or manipulation of its tasks in several
science and health fields, getting significant discoveries about treatment for certain diseases.
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CHAPTER II - GLYCINE’S RELEVANCE

2.1 The impor tance of glycine tr anspor ter s in neur ological disor der s
As mentioned, it is essential to understand the function and development of the glycine
transporters in the CNS. Scientists have been looking for new ways to inhibit the activity of
GlyTs in order to understand their importance in the central nervous system. In the case of
GlyT1, its inhibition has been studied for its relationship against several diseases such as
schizophrenia (Hashimoto, 2010), which in the inhibition of GlyT1, the extracellular glycine
concentration increased and the NMDA response increased too, showing an essential
modulation of NMDA receptors by glycine transporters (Lim et al., 2004).
On the other hand, the inhibition of GlyT2 has been studied concerning its high
co-relation with neurological diseases such as chronic pain (Cioffi, 2017). Vandenberg,
Robert J., et al., 2014 showed how the population that suffers from chronic pain increases in
the last years. It has a powerful influence on other diseases such as depression, anxiety, and
cognitive dysfunction. GlyT2 is involved in glycinergic inhibitory neurotransmission, an
essential pathway in the maintaining of pain control.
The importance and understanding of glycine transporters in the mammalian central
nervous system are indispensable in search of new treatments against certain neurological
diseases such as hyperekplexia (Schwarcz, 2016). In this project, we focus primarily on the
development of GlyT2 inhibitors. Our goal is to produce new therapies for the treatment of
chronic pain, which helps decrease the use of several pharmaceutic treatments such as
anticonvulsants, antidepressants, NMDA receptor antagonists, and opioids.
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GLYCINE TRANSPORTERS AND CHRONIC PAIN

Figur e 2. Inhibition of GlyT2 suppr essing pain signals. A) Glycine receptors regulate pain
signals transmitted by the projection neurons located in the superficial layers of the dorsal
horn. B) Inhibition of glycine transporter 2 (GlyT2) potentiates the activation of glycinergic
inhibitory neurotransmission by reducing the reuptake of glycine from glycinergic synapses,
which further inhibits the firing of projection neurons and thereby suppresses pain. C)
Reuptake of glycine by GlyT2 from glycinergic synapses.
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The inserts depict local glycinergic transmission in the absence (top panel) and presence
(bottom panel) of glycine reuptake inhibition. Blockade of GlyT2, as shown in the top panel
of the insert, does not seem to impair vesicular refilling of glycine at the presynaptic
terminals and therefore does not limit presynaptic glycine release. Nociceptive C‐ and Aβ
fibers stimulate the pain projection neuron and activate glycinergic interneurons that inhibit
the pain projection neuron. The activation of glycinergic interneurons via NMDA
(N‐methyl‐d‐aspartate) receptors may be strengthened by a suggested GlyT1 inhibition,
thereby providing additional inhibition of the pain signals destined for the brain.
2.2 Glycine over opioids use on tr eatments for chr onic pain
Opioids have been one of the most controversial topics discussed between scientists;
their use divides still this time every debate about functional and efficient treatments for
chronic pain. Considered as the regular treatment for severe pain or chronic pain, opioids are
not well thought out to been used for long-term administration (Rosenblum, Marsch, Joseph,
& Portenoy, 2008). Opioids' side effects are affiliated to safety or addiction from the
consumers. It is has been the principal factor in order to provide a detailed analysis of the
mechanism of them. The side effects of opioids in long-term treatments such as chronic pain
or diseases like cancer have been a severe problem. It made scientists look forward to new
treatments avoiding the use of opioids. Glycine inhibition has not been involved in the
activation of neuronal mechanisms that affect the emotional stability of improving human
addiction. Opioids showed to be involved in specific mechanisms in the central nervous
system, specifically the amygdala (Proehlich, 2017), and altered the modulation of feelings
on the brain, producing an artificial sensation of euphoria on patients.
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AIMS

AIM 1) The Inhibition of glycine tr anspor ter 2 with Zinc molecules.
One of the primary purposes of this project is to understand the interaction and the
inhibition of glycine transporters (especially glycine transporter type 2) in contact with
several inhibitors; to analyze the efficiency of the inhibitors to obtain a possible target in the
exploration of new treatments for chronic pain relief. We will examine four promising
compounds (selected by screening over 3.5 million lead like compounds from the ZINC15
library) to hit that may inhibit the glycine transporter two and possible selectivity over
GlyT1.
a) ZINC6620309 (HIT 1)
b) ZINC6865169 (HIT2)
c) ZINC30678404 (HIT3)
d) ZINC1606495 (HIT4)
AIM 2) Glycine tr anspor ter 1 inhibition to test selectivity for glycine tr anspor ter 2.
To obtain accurate data is necessary for the analysis of several factors. It is essential the
analyze how the four promising compounds interact with glycine transporter type 1 to get a
more specific view of the specificity of those compounds in the interaction with both glycine
transporters.
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AIM 3 ) Cytotoxicity analysis on HIT 1-3 compounds.
Following the process of satisfaction in those possible treatment targets, it is essential to
analyze cytotoxicity, showing acceptable results of not side effects, looking for the agreement
of safety in the use of Zinc molecules. Subsequently, studying how the compounds interacted
in the glycine transporter inhibition process, it was also necessary to analyze the compounds'
toxicity to be considered possible factors for chronic pain treatments.
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METHODS AND PROCEDURE

Virtual screening. To find the best inhibitors for GlyT2, the virtual screening technique
was used. The computational method is used to discover drugs from libraries of molecules,
helping identify the most likely to bind to our target. The process starts at the begging of a
free database (ZINC15 library) of available and commercial compounds for virtual screening.
As a cone, the system begins to get rid of those compounds that do not have the affinity
necessary in the methodology of selection and specification for an inhibitor of GlyT2.

Molecular docking. For a good characterization of new GlyT2 inhibitors, we will
combine the use of computational methodologies such as Molecular docking and biochemical
assays to obtain a full characterization and interaction of 4 potential inhibitors for GlyT2.
Molecular docking will help us in the understanding of the molecular interaction of the
inhibitors with the glycine transporter 2, and with the use of induced-fit docking (IFD) can be
possible to evaluate the stability of those four ZINC inhibitors.

In vitro assay. To follow a correct improvement in the experiments, it is necessary to
start with several in vitro assays with selective GlyT1 inhibitor ALX5407 and GlyT2
inhibitor ALX1393. Human GlyT2 gene will be cloned into the expression vector pcDNA3.1
and used it for transfection and selection of porcine endothelial aortic (PAE) cells. PAE cells
were selected as our preferred model cells based on their plastic stability and low
over-expression of ectopic proteins. The reaction buffer will be a mix of 4uci[H3] glycine/ml
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isotope and cold glycine stock solution. The [3H] glycine is extracted from the cells by
adding 250µL of NaOH. Glycine uptake will be determined by a scintillation spectroscopy
machine analyzing the samples with the help of 100µL lysate in 4ml of scintillation cocktail.

Cytotoxicity. Differential nuclear staining (DNS) assay to quantify cytotoxicity. It is
necessary to gently wash the PAE cells that will be used on the experiment with a fresh
medium. The mid-exponential phase of the cells for the experiment with a 60 to 70%
confluence will be sufficient. The wash is necessary to remove any debris and floating cells
to obtain a better analysis (Lema et al. 2011). Following the protocol trypsinization, harvest,
and count the cells using the Neubauer chamber. Then, into a 96-well tissue culture plate at a
density of 10,000 cells/well, add 100 μl of complete medium. The culture plate should be
incubated overnight. The next day, the cells should be exposed to a concentration gradient of
the HIT compounds and ALX inhibitor 24 hours. It was necessary to add Hoechst and
propidium iodide (PI) at a final concentration of 1 ug/ml to each well two hours before the
plate reading. (Gutierrez et al., 2019). Next, using a bioimager (BD Pathway 855 system; BD
Biosciences) equipped with a 10x objective will be used to capture 3x3 montages in two
fluorescence channels, the fluorophores excitation, and emission wavelength. Finally, the
Attovison software (BD Biosciences) is used in this case to get both the image capture and
their analysis to find out the percentage of cytotoxicity per individual well (Robles-Escajeda
et al. 2016).
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CHAPTER III - RESULTS
The virtual screening technique gave the beginning of finding the possible compounds to
use as inhibitors of the glycine transporter 2. In the free database (ZINC15 library) is found
around 3.5 million potential compatible compounds. From there, the compounds are analyzed
based on docking simulation, and 35,000 compounds were possible options for inhibitors.
Just 100 scoring ligands were selected for better development, and finally, for those 100, only
20 ligands were obtained from the induced fit-docking looking for the best specification from
the compounds. Yet, four compounds (2 different classes of ligands) were selected with the
most possible specificity as a GlyT2 inhibitor.
The use of molecular docking was necessary to confirm the way of how the compounds
possibly would interact with our target (GlyT2) based on several aspects, such as their
chemical structure (figure 3)—confirming that our selected compounds would cancel the
glycine binding site affinity. After MD simulations, it was necessary to prove the in-vitro
assays' results, starting with the known inhibitor of the glycine transporter 2, ALX1393.
Using the control (ALX1393) on our experiments was possible to obtain more accurate
results, for the assays were used epithelial cells, which expressed the human GlyT2. It was
observed an IC50 of 25.9nM, value approved by literature data(Mingorance-Le Meur et al.,
2013).
First, it was necessary to analyze in detail the glycine transporter 2, seeking to verify the
position and interaction of the third sodium binding site, which is one of the main factors that
differentiate it from the glycine transporter 1. As a result of several MD studies, the third Na+
14

ion position could be observed, and it was guided mainly by GLU248, Met276, Trp263, and
Glu648 (Fratev, Miranda-Arango, Lopez, Padilla, & Sirimulla, 2019). An exhaustive analysis
of this third sodium ion was sought since the glycine transporter 1 does not present it. It was
essential to support our hypothesis about how this third sodium binding site could be more
stable for the four compounds to be treated. Data that could be possible thanks to several
molecular docking simulations on the GlyT1 that does not have that third Na+ ion (Fratev,
Miranda-Arango, Lopez, Padilla, & Sirimulla, 2019).
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CHEMICAL STRUCTURE OF LIGANDS

ZINC6620309-HIT1

ZINC6865169-HIT2

ZINC30678404-HIT3

ZINC1606495-HIT4

Figur e 3. Chemical str uctur al of the four Hits (1-4) by VS. Visual screening method was
used in order to identify the chemical structure of each compound.

16

It was acquiring the chemical structures of the compounds, as shown in figure 3. It was
an indispensable aid in the respective MD, and virtual screening analyzes were carried out to
verify the interactions between the four compounds and the glycine transporter 2. The first
class of ligands was tested; the Hit1/Lead1 or ZINC6620309 showed an average of IC50 =
0.48μM, then, Hit2/Lead2, or ZINC6865169 showed an average of IC50 = 0.52μM; one of
the possible reasons should be the difference in its structure comparing to Hit1; having two
carbons atoms extra after the propionic acid segment (Figure 3). Then,

the

next

two

compounds were analyzed; Hit3/Lead3 or ZINC30678404 showed an average of IC50 = 33.2
μM higher than the first two ligands because of its closed interaction with the first Na+ atom
of the GlyT2. Finally, HIT4/Lead4 or ZINC1606495 did not show good interaction as an
inhibitor for GlyT2. After several experiments, we observed, based on the experiments, that
HIT4 did not inhibit GlyT2.
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GlyT2 ACTIVITY WITH ALX 1393 INHIBITOR

Figur e 4. Inhibition of GlyT2 activity by ALX1393 inhibitor . The graph shown is
representative of 3 independent experiments. Porcine endothelial aortic cells (PAE cells)
were used for the expression of the human glycine transporter two at several concentrations
(0.0001 μM - 100 μM). Based on in-vitro experiments calculating IC50 based on the
sigmoidal curves obtained.
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GlyT2 ACTIVITY WITH HIT1/LEAD1 COMPOUND

Figur e 5. GlyT2 activity by HIT1/LEAD1 compound. Porcine endothelial aortic cells
(PAE cells) were used for the expression of the human glycine transporter 2 at several
concentrations (0.5 μM - 500 μM). Based on in-vitro experiments calculating IC50 based on
the sigmoidal curves obtained. The graph shown is representative of 3 independent
experiments.
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GlyT2 ACTIVITY WITH HIT2/LEAD2 COMPOUND

Figur e 6. Inhibition of GlyT2 activity by HIT2/LEAD2 compound. The graph shown is
representative of 3 independent experiments. Inhibition of GlyT2 activity by HIT2/LEAD2
compound with porcine endothelial aortic cells (PAE cells) used for the expression of the
human glycine transporter 2 at several concentrations (0.5 μM - 500 μM). Based on in-vitro
experiments calculating IC50 based on the sigmoidal curves obtained.

20

GlyT2 ACTIVITY WITH HIT3/LEAD3 COMPOUND

Figur e 7. Inhibition of GlyT2 activity by HIT3/LEAD3 compound. The graph shown is
representative of 3 independent experiments. Inhibition of GlyT2 activity by HIT3/LEAD3
compound with porcine endothelial aortic cells (PAE cells) used to express the human
glycine transporter 2 at several concentrations (0.5 μM - 500 μM). Based on in-vitro
experiments calculating IC50 based on the sigmoidal curves obtained.
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GlyT2 ACTIVITY WITH HIT4/LEAD4COMPOUND

Figur e 8. GlyT2 activity with HIT4/LEAD4 compound. Porcine endothelial aortic cells
(PAE cells) were used for the expression of the human glycine transporter 2 at several
concentrations (0.5 μM - 500 μM). Based on in-vitro experiments was confirmed no
inhibition from the HIT4 compound. The graph shown is representative of 3 independent
experiments.
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Continuing to analyze the specificity of these compounds, we tried the same compounds
on the GlyT1. Based on the very close similarities between both transporters, the specificity
of a compound is one of the must address essential concerns. It is known that when seeking to
confirm the specificity of an inhibitor of a specific glycine transporter, it is fundamental and
indispensable to analyze its interaction with the glycine transporter opposite to be treated.
That is why the next step on this project was based on test the four HIT compounds as on
previews experiments but now with an inhibitor known as specific for GlyT1; ALX5407
(Kopec et al., 2009).
As we expected, the ALX5407 was tested on a mammalian cell line. It worked at low
concentration (IC50:14 nM) as it is known in the literature that it is normal (Kopec et al.,
2009). Looking for our compounds' specificity, we tested the four compounds at the same
concentrations from the last experiments for GlyT2, but on cells expressing glycine
transporter 1. The results were favorable to the project; Hits 1-3 did not show any inhibition
activity, as expected. Furthermore, Hit4 showed inhibition activity for glycine transporter 1.
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GlyT1 ACTIVITY WITH ALX5407 INHIBITOR

Figur e 9. Inhibition of GlyT1 activity by ALX5407 inhibitor . The graph shown is
representative of 3 independent experiments. Porcine endothelial aortic cells (PAE cells)
were used for the expression of the human glycine transporter 1 at several concentrations (0.1
nM - 200 nM). Based on in-vitro experiments calculating IC50 based on the sigmoidal curves
obtained.
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GlyT1 ACTIVITY WITH HIT1/LEAD1 COMPOUND

Figur e 11. GlyT1 activity with HIT1/LEAD1 compound. Porcine aortic endothelial cells
(PAE) cells are used for the expression of the human glycine transporter 1 at several
concentrations (0.5 μM - 500 μM). Based on in-vitro experiments, no presence of inhibition
activity from the HIT1 compound on glycine transporter 1. The graph shown is representative
of 3 independent experiments.
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GlyT1 ACTIVITY WITH HIT2/LEAD2 COMPOUND

Figur e 12. GlyT1 activity with HIT2/LEAD2 compound. Porcine aortic endothelial cells
(PAE) cells are used for the expression of the human glycine transporter 1 at several
concentrations (0.5 μM - 500 μM). Based on in-vitro experiments, no presence of inhibition
activity from the HIT2 compound on glycine transporter 1. The graph shown is representative
of 3 independent experiments.
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GlyT1 ACTIVITY WITH HIT3/LEAD3 COMPOUND

Figur e 13. GlyT1 activity with HIT3/LEAD3 compound. Porcine aortic endothelial cells
(PAE) cells are used for the expression of the human glycine transporter 1 at several
concentrations (0.5 μM - 500 μM). Based on in-vitro experiments, no presence of inhibition
activity from the HIT3 compound on glycine transporter 1. The graph shown is representative
of 3 independent experiments.
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GlyT1 ACTIVITY WITH HIT4/LEAD4 COMPOUND

Figur e 10. GlyT1 activity with HIT4/LEAD4 compound. Porcine aortic endothelial cells
(PAE) cells are used for the expression of the human glycine transporter 1 at several
concentrations (0.5 μM - 500 μM). Based on in-vitro experiments was confirmed an
inhibition activity from the HIT4 compound on glycine transporter 1.
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Continuing with the exhaustive analysis on the search for the specification of each
compound towards glycine transporters. The next step to be considered in this project was the
cytotoxicity analysis of the treated compounds (HIT1, HIT2, HIT3). It is well known that in
order to carry out a complete process in the pharmacological area of acceptance of any
treatment, the pertinent analyzes must be carried out regarding the toxicological effects that
they would have on humans. Furthermore, if said would be considered acceptable for said
treatment to be considered for possible use in the medicinal field.
Following the process, only the HIT1-3 compounds showed favorable inhibition results
to the glycine transporter 2 and followed by the fact that the results favor a selectivity only
for the glycine transporter 2. A series of treatments on cytotoxicity was performed on the
compounds to know how feasible the compounds' possible use is later in chronic pain
treatments.
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CYTOTOXICITY OF HIT COMPOUNDS ON PAE CELLS

Figur e 14. Thr ee HIT compounds and ALX inhibitor wer e tested for their capacity to
inflict cytotoxicity on PAE cells. Expose the cells to the concentration gradient (in µM) of
each inhibitor and incubate for 24 hours. Differential nuclear staining and bioimaging system
(BD Pathway 855) are used to determine the percentage of cytotoxicity (y-axis). When the
experimental samples were compared with 1% v/v PBS solvent (*) and untreated (Unt.) (‡)
control cells, the P values

were <0.001 and <0.001, respectively. Cells treated with 1 mM

H2O2 were used as a positive control for cytotoxicity. Each experimental point represents the
average of four replicates, and the error bar represents its corresponding standard
deviation—experiments and analysis by a collaboration with Dr. Armando Varela.
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CONCLUSION
All in all, these data together prove that the structure of the project has high quality. The
first four compounds' development showed the efficient possible work made by using
homology/MD-derived structures. Our visual screening method can still result in a high hit
rate of 75%. Allowing us to discover a set of new compounds with good inhibitory properties
and selectivity can be further optimized in the analysis of more and more new compounds,
looking for possible targets for chronic pain treatments. Furthermore, Hit1 was considered the
first and principal candidate for further optimizing potential customers and making a detailed
and more specific analysis on that ligand.
We observed some factors that made Hit1 a primary ligand, such as the stable hydrogen
bonds interacting with glycine transporter 2, showing a similar development to ALX1393
activity. Through several MD simulations. Exciting interactions between the ligand and
several residues can be observed. The carbonyl group of Hit1 interacted with three residues
Leu211, Gly212, Tyr287, and the first sodium of the receptor, too; interactions showed
similarities with those of ALX1393 activity.
These results provide a structural basis for the Hit1 selectivity observed experimentally
in GlyT2. Hit2 showed the closest results to Hit1. We considered some factors, such as the
carbonyl group's orientation and the missing of one oxygen in the ring structure. Moreover,
the lack of interaction with one of the compounds (HIT4) could be observed. In the
interest-based on their stoichiometry similarities, you can make the mistake of assuming that
if it works with a glycine transporter when in fact, it would be inhibiting both transporters,
bringing severe damage to the subject to whom it was supplied.
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Situation for which, we made the decision to try four HIT compounds in interaction with
the glycine transporter 1 to check if said compound ultimately had no interaction with the two
glycine transporters or indeed demonstrated an inhibiting interaction with the glycine
transporter 2 and the glycine transporter 1 too. As could be observed in the beneficial
pertinent experiments, it was shown that the HIT4 compound was more refined to an
interaction with the glycine transporter 1 and not as we assumed with the transporter of
glycine 2 the three compounds before that interacted. Besides, it could be shown that the
other three compounds did not lead to any interaction with glycine transporter 1.
Finally, our research shows that the combination of structure-based pharmacophores and
docking technology can help identify new biologically active and selective compounds. This
combination allows us to identify new and selective GlyT2 inhibitors. The FEP+ method
provides detailed insights into the structural basis of selectivity and proposes ideas for further
optimization of leads.
The in-vitro assays were very useful in the analysis of the inhibition interaction from the
different compounds to the glycine transporters. Confirming the interaction efficiency of the
compounds showed on the docking technology and the FEP+ method. Corroborative the idea
that it is possible to find new treatment targets for chronic pain and decrease the uncontrolled
use of opioids as the first conventional option to treat chronic pain. Although there is high
sequence similarity between the binding sites of GlyT2 and GlyT1, on our project, one of the
main aspects to be considered was the specificity of the compounds tested.
The experimental data of the Hit1 compound that we found shows that it is a highly
selective GlyT2 inhibitor. The difference between the binding sites of these transporters
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(GlyT1 and GlyT2) subclasses is only five residues. Therefore, Hit1 is an ideal compound to
reveal selectivity. Thanks to the experiments on cytotoxicity that were carried out, the HIT
compounds obtained favorable results, which bring us closer to good possibilities of using the
compounds as treatment—showing data in low concentrations a good development of the
three compounds interacted favorably with the glycine transporter 2. The graph shows as in
comparison with the positive, negative controls and the untreated cells.
The interaction of these compounds show similarities with ALX1393. This series of
virtual analyzes on molecules, as well as in-vitro experiments and cytotoxicity, help to
consolidate further the idea that there are more possibilities to achieve new possible
alternatives for chronic pain treatments. Avoiding a relapse into the use of opioids, improving
patients' opportunities to lead a life free of secondary complications, and more stable
lifestyles. If it is true that there is still much to know about new alternatives for the treatment
of chronic pain, this project has been another step in that search.
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GLOSSARY

CNS: Central nervous system is the segment of the nervous system that involves the brain
stem, spinal cord and cerebellum.
GlyT: Glycine transporter require on the transport of glycine.
GlyT1: Glycine transporter 1 is located on the glial cells, astrocytes and post-synaptic
terminals, the excitatory synapses of glycine on the central nervous system are controlled by
this transporter.
GlyT2: Glycine transporter 2 is located on the presynaptic terminals, the inhibitory synapses
of glycine on the central nervous system are controlled by this transporter.
IFD: known as the Induced-fit docking a computational technique of the virtual docking
studies about the interaction between molecules.
MD: Molecular docking, computational technique used on the analysis finding the most
stable complex between a molecules interaction.
NMDA: N-methyl-D-aspartate is a glutamate receptor found the nerve cells.
PAE: the Porcine endothelial aortic cells are considered as a stable line of cells used on the
study of several systems
PI: the propidium iodide is a red fluorescent dye, not permeant to live cells, that detects
damage membrane cells.
SLC6: Solute carrier 6 family is one of the extended family of homologous transporters that
includes many prokaroytic transporters.
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